Clinical Benefit within Patient Subgroups Receiving c7E3 Fab (Abciximab) During Percutaneous Coronary Revascularization: Subgroup Analysis from the EPIC Trial.
Aguirre
FV
J.G. Mudd Cardiac Catheterization Laboratory, St. Louis University Health Sciences Center, 3635 Vista Avenue at Grand, St. Louis, MO, 63110, USA.
Topol
EJ
Anderson
KM
Kleiman
NS
Weisman
HF
FitzPatrick
SE
Califf
RM